108 results
8-K
EX-99.1
ARVN
Arvinas Inc
16 May 24
Regulation FD Disclosure
6:05am
, as a monotherapy and in combination studies; and statements regarding potential therapeutic benefits of vepdegestrant. All statements, other than statements … ), a global collaboration between Pfizer and Arvinas to develop and commercialize vepdegestrant and Pfizer Oncology, including their potential benefits
8-K
ARVN
Arvinas Inc
18 Mar 24
Departure of Directors or Certain Officers
4:45pm
rights, non-disclosure, developments, non-competition and non-solicitation agreement, Dr. Peck will be entitled to the severance benefits provided … under his employment agreement in connection with a termination of his employment without cause or for good reason. These severance benefits include
8-K
EX-99.1
lpl2tewrgvsxndg8pjmm
27 Feb 24
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
7:02am
8-K
veq5l85g hixxb
20 Feb 24
Departure of Directors or Certain Officers
4:06pm
S-8
EX-99.4
xncv8f2kf8qpb7v
16 Jan 24
Registration of securities for employees
4:03pm
S-3ASR
0mnth
8 Dec 23
Automatic shelf registration
9:16am
8-K
EX-99.2
yf07vi4faetyp jfl
6 Dec 23
Regulation FD Disclosure
7:01am
8-K
zff w18r6bt9
6 Dec 23
Regulation FD Disclosure
7:01am
8-K
EX-99.1
ra4cx1ktgkzm0j y9d91
6 Dec 23
Regulation FD Disclosure
7:01am
8-K
EX-10.2
b5a5i3g8 ne5
27 Nov 23
Arvinas Announces Oversubscribed $350 Million Private Placement
7:11am
S-3ASR
EX-4.4
cxqouyht0a0i1t
7 Nov 23
Automatic shelf registration
5:24pm
S-3ASR
EX-1.2
hpd71n2xy6l kdehmic
7 Nov 23
Automatic shelf registration
5:24pm
S-3ASR
h3ke0m5r2nxoth3y
7 Nov 23
Automatic shelf registration
5:24pm
S-3ASR
EX-4.5
h13v6dpvis mxepzgik
7 Nov 23
Automatic shelf registration
5:24pm